Format

Send to

Choose Destination
Heart Fail Clin. 2009 Oct;5(4):579-88. doi: 10.1016/j.hfc.2009.04.004.

Newer biomarkers in heart failure.

Author information

1
The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Abstract

The pathophysiology of heart failure is complex, and the list of biomarkers representing distinct pathophysiologic pathways is growing rapidly. This article focuses on some promising newer biomarkers that have contributed to a better understanding of pathophysiologic mechanisms involved in heart failure but for which less data are currently available: osteoprotegerin, galectin-3, cystatin C, chromogranin A, and the adipokines adiponectin, leptin, and resistin. Despite the intriguing early information from these newer markers, none is ready for routine clinical use. Much additional study is needed to determine how these biomarkers will fit into diagnostic and treatment algorithms for patients who have heart failure.

PMID:
19631181
DOI:
10.1016/j.hfc.2009.04.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center